Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chinese Chain Drugstore Gets Capital Injection

This article was originally published in PharmAsia News

Executive Summary

Kaixinren, a China drugstore chain, has received a 80 million yuan injection from a Japanese venture capital firm, according to reliable sources. Kaixinren will use the funds to expand and make acquisitions. The company will further raise 200 million yuan this year, aiming to go public in 2009. In recent years, drugstore chains have been losing their low-price advantage and market share. Management issues, lack of funds and industrial talents constitute roadblocks to development. Analysts feel that the only way to invigorate the industry is through improved core competitiveness and formation of large-scale enterprises, driven by capital operation. They advise that chains need a long-term investment strategy, backed by a cautious approach toward expansion. (Click here for more)

You may also be interested in...

Guardant Health Expects FDA Approval Of Liquid Biopsy Test Will Strengthen Coverage, Adoption

Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.

Finance Watch: CureVac’s IPO Is Ready For Launch

Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m. 

US FDA's Hahn Promotes Provider Role In Boosting Public Confidence In COVID-19 Products

Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts